XFOR X4 Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why XFOR matters now
X4 Pharmaceuticals, Inc. (XFOR) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.41 with +11.36% on the session and $415.9M in market capitalization; recent performance reads 1-month +15.93% and YTD +5.50%.
The latest financial table shown here is Q1 2026, with revenue of $2.7M, net income of $-20.2M, and EPS of $-0.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.4%.
The latest indexable market news headline is "X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes KIRSKE DAVID filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.16
P/S
44.16
EV/EBITDA
-2.88
DCF Value
$22.13
FCF Yield
-18.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.4%
Operating Margin
-1084.4%
Net Margin
-1106.3%
ROE
-94.9%
ROA
-36.9%
ROIC
-39.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.7M | $-20.2M | $-0.16 |
| Q4 2025 | $2.6M | $-23.9M | $-0.22 |
| FY 2025 | $35.1M | $-79.2M | $-1.87 |
| Q3 2025 | $1.8M | $-29.8M | $-0.69 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.37
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.